Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 151 AL 165

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment

Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.

J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924.

Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease

Batool A, Kamal MA, Rizvi SMD, Rashid S.

Curr Drug Metab. 2018;19(8):704-713. doi: 10.2174/1389200219666180305152553.

TNF alpha inhibitors in Alzheimer's disease: A systematic review

Ekert JO, Gould RL, Reynolds G, Howard RJ.

Int J Geriatr Psychiatry. 2018 May;33(5):688-694. doi: 10.1002/gps.4871. Epub 2018 Mar 7.

Alzheimer dementia: Starting, stopping drug therapy

Kim LD, Factora RM.

Cleve Clin J Med. 2018 Mar;85(3):209-214. doi: 10.3949/ccjm.85a.16080.

Editorial: Signaling Molecules as Biomarkers and Therapeutic Targets for Alzheimer's Disease: A New Perspective

Moreno S.

Curr Alzheimer Res. 2018 Feb 22;15(4):302. doi: 10.2174/156720501504180222162435.

Profiling donepezil template into multipotent hybrids with antioxidant properties

Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, Malinak D, Janockova J, Jun D, Kuca K, Korabecny J.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):583-606. doi: 10.1080/14756366.2018.1443326.

Alzheimer-Demenz – die kognitiven «Enhancer» haben kaum einen positiven Effekt auf den weiteren Verlauf

Steurer J.

Praxis (Bern 1994). 2018;107(6):335-336. doi: 10.1024/1661-8157/a002919.

Combining drug and music therapy in patients with moderate Alzheimer's disease: a randomized study

Giovagnoli AR, Manfredi V, Schifano L, Paterlini C, Parente A, Tagliavini F.

Neurol Sci. 2018 Jun;39(6):1021-1028. doi: 10.1007/s10072-018-3316-3. Epub 2018 Mar 17.

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer's disease

Chang W, Teng J.

Drug Des Devel Ther. 2018 Mar 5;12:455-462. doi: 10.2147/DDDT.S155567. eCollection 2018.

Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future

Cummings J, Ritter A, Zhong K.

J Alzheimers Dis. 2018;64(s1):S3-S22. doi: 10.3233/JAD-179901.

Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies

Nisbet RM, Götz J.

J Alzheimers Dis. 2018;64(s1):S517-S527. doi: 10.3233/JAD-179907.

Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease

Gong CX, Liu F, Iqbal K.

J Alzheimers Dis. 2018;64(s1):S107-S117. doi: 10.3233/JAD-179921.

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW, Bun RS, Cacciola F, Cavedo E, Chiesa PA, Colliot O, Coman CM, Dubois B, Duggento A, Durrleman S, Ferretti MT, George N, Genthon R, Habert MO, Herholz K, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehéricy S, Lorenceau J, Neri C, Nisticò R, Nyasse-Messene F, Ritchie C, Rossi S, Santarnecchi E, Sporns O, Verdooner SR, Vergallo A, Villain N, Younesi E, Garaci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2018;64(s1):S47-S105. doi: 10.3233/JAD-179932.

A Novel Therapeutic Approach to Treat Alzheimer's Disease by Neurotrophic Support During the Period of Synaptic Compensation

Baazaoui N, Iqbal K.

J Alzheimers Dis. 2018;62(3):1211-1218. doi: 10.3233/JAD-170839.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias